Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two Decades

被引:87
作者
Valdez, Jessica M. [3 ,4 ]
Scheinberg, Phillip [5 ]
Nunez, Olga [5 ]
Wu, Colin O. [6 ]
Young, Neal S. [5 ]
Walsh, Thomas J. [1 ,2 ,4 ]
机构
[1] Cornell Univ, Transplantat Oncol Infect Dis Program, Weill Cornell Med Coll, New York, NY 10065 USA
[2] New York Presbyterian Hosp, New York, NY USA
[3] NCI, Howard Hughes Med Inst, Natl Inst Hlth Res Scholars Program, Bethesda, MD 20892 USA
[4] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA
[5] NHLBI, Hematol Branch, Bethesda, MD 20892 USA
[6] NHLBI, Off Biostat Res, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; COLONY-STIMULATING FACTOR; LIPOSOMAL AMPHOTERICIN-B; ANTI-THYMOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; IMMUNOSUPPRESSIVE THERAPY; ANTIFUNGAL THERAPY; ANTILYMPHOCYTE GLOBULIN; PERSISTENT FEVER;
D O I
10.1093/cid/ciq245
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Persistent neutropenia associated with severe aplastic anemia (SAA) is an important risk factor for development of life-threatening infections. Earlier studies underscored the high mortality associated with invasive fungal infections (IFIs) in SAA. However, little is known about the current patterns of infections and the impact of advances in anti-infective therapy on survival in SAA. Methods. We reviewed the records of 174 patients with SAA admitted to the Hematology Branch at NHLBI from 1989 to 2008 who were unresponsive to initial immunosuppressive therapy (IST) at 6 months. Three patient groups determined by IST protocol and time interval were compared: group 1 (43 patients; December 1989-October 1996), group 2 (51 patients; November 1996-October 2002), and group 3 (80 patients; November 2002-April 2008). Outcome variables included infections, patterns of resistance, survival, and infection-related mortality. Results. During the past 2 decades, infection-related mortality decreased from 37% in group 1 to 11% in group 3 (P<.001), and the frequency of IFIs decreased from 49% in group 1 to 8% in group 3 (P<.001). Overall 5-year survival for all patients (n = 420) increased from 64% in group 1 to 79% in group 3 (P<.001). Among nonresponders (n = 174), it increased from 23% in group 1 to 57% in group 3 (P<.001). In multivariate analysis, younger age, absolute neutrophil count >200 cells/mu L before IST, absence of IFIs, and use of voriconazole were independently predictive of survival. Conclusion. During the past 2 decades, there has been a significant decrease in IFIs, infection-related mortality, and overall mortality in patients with SAA unresponsive to initial IST.
引用
收藏
页码:726 / 735
页数:10
相关论文
共 26 条
[1]   Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients [J].
Bacigalupo, A ;
Bruno, B ;
Saracco, P ;
Di Bona, E ;
Locasciulli, A ;
Locatelli, F ;
Gabbas, A ;
Dufour, C ;
Arcese, W ;
Testi, G ;
Broccia, G ;
Carotenuto, M ;
Coser, P ;
Barbui, T ;
Leoni, P ;
Ferster, A .
BLOOD, 2000, 95 (06) :1931-1934
[2]   BONE-MARROW TRANSPLANTATION (BMT) VERSUS IMMUNOSUPPRESSION FOR THE TREATMENT OF SEVERE APLASTIC-ANEMIA (SAA) - A REPORT OF THE EBMT SAA WORKING PARTY [J].
BACIGALUPO, A ;
HOWS, J ;
GLUCKMAN, E ;
NISSEN, C ;
MARSH, J ;
VANLINT, MT ;
CONGIU, M ;
DEPLANQUE, MM ;
ERNST, P ;
MCCANN, S ;
RAGAVASHAR, A ;
FRICKHOFEN, N ;
WURSCH, A ;
MARMONT, AM ;
GORDONSMITH, EC .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (02) :177-182
[3]   QUANTITATIVE RELATIONSHIPS BETWEEN CIRCULATING LEUKOCYTES AND INFECTION IN PATIENTS WITH ACUTE LEUKEMIA [J].
BODEY, GP ;
BUCKLEY, M ;
SATHE, YS ;
FREIREICH, EJ .
ANNALS OF INTERNAL MEDICINE, 1966, 64 (02) :328-+
[4]   Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia [J].
Brodsky, RA ;
Sensenbrenner, LL ;
Smith, BD ;
Dorr, D ;
Seaman, PJ ;
Lee, SM ;
Karp, JE ;
Brodsky, I ;
Jones, RJ .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (07) :477-483
[5]   Empirical versus Preemptive Antifungal Therapy for High-Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial [J].
Cordonnier, Catherine ;
Pautas, Cecile ;
Maury, Sebastien ;
Vekhoff, Anne ;
Farhat, Hassan ;
Suarez, Felipe ;
Dhedin, Nathalie ;
Isnard, Francoise ;
Ades, Lionel ;
Kuhnowski, Frederique ;
Foulet, Francoise ;
Kuentz, Mathieu ;
Maison, Patrick ;
Bretagne, Stephane ;
Schwarzinger, Michael .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (08) :1042-1051
[6]  
DONEY K, 1987, EXP HEMATOL, V15, P239
[7]   TREATMENT OF APLASTIC-ANEMIA WITH ANTILYMPHOCYTE GLOBULIN AND METHYLPREDNISOLONE WITH OR WITHOUT CYCLOSPORINE [J].
FRICKHOFEN, N ;
KALTWASSER, JP ;
SCHREZENMEIER, H ;
RAGHAVACHAR, A ;
VOGT, HG ;
HERRMANN, F ;
FREUND, M ;
MEUSERS, P ;
SALAMA, A ;
HEIMPEL, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (19) :1297-1304
[8]  
Kojima S, 2000, BLOOD, V96, P2049
[9]   EMPIRIC ANTIBIOTIC AND ANTIFUNGAL THERAPY FOR CANCER-PATIENTS WITH PROLONGED FEVER AND GRANULOCYTOPENIA [J].
PIZZO, PA ;
ROBICHAUD, KJ ;
GILL, FA ;
WITEBSKY, FG .
AMERICAN JOURNAL OF MEDICINE, 1982, 72 (01) :101-111
[10]   Advances in Antibacterial Therapy Against Emerging Bacterial Pathogens [J].
Pournaras, Spyros ;
Iosifidis, Elias ;
Roilides, Emmanuel .
SEMINARS IN HEMATOLOGY, 2009, 46 (03) :198-211